Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
LOOKING FORWARD
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
Puma Biotechnology Surging
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Puma Biotechnology: Profitable, Troubled, But Worth A Good Look (NASDAQ:PBYI) | Seeking Alpha
PumaBiotech (@pumabiotech) / X
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Why Shares in Puma Biotechnology Inc. Are Plunging | The Motley Fool
Puma Biotechnology
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
Mission Accomplished – 365 Days on Nerlynx – Ela K. Browder
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | Clinical Drug Investigation
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
Nerlynx: Package Insert - Drugs.com
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | The Motley Fool
Puma Biotechnology
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib)
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
